Keytruda combination hits primary endpoint in a rare form of gastric cancer

Mer­ck’s Keytru­da notched an­oth­er pos­i­tive set of da­ta, this time in a rare can­cer of the esoph­a­gus that sets up the com­pa­ny to re­ceive full ap­proval in this in­di­ca­tion.

The drug­mak­er an­nounced Fri­day that a Phase III tri­al in­ves­ti­gat­ing Keytru­da in com­bi­na­tion with Her­ceptin and chemo met one of two pri­ma­ry end­points for pro­gres­sion-free sur­vival as a first-line of treat­ment for gas­tric or gas­troe­sophageal junc­tion (GEJ) ade­no­car­ci­no­ma.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN